Monte Rosa Therapeutics (GLUE) Income from Continuing Operations (2020 - 2026)
Monte Rosa Therapeutics' (GLUE) quarterly Income from Continuing Operations came in at 44551000.0 in Q1 2026, down 195.02% year-on-year from 46885000.0 in Q1 2025, and down 51.08% quarter-over-quarter from 29489000.0 in Q4 2025.
Monte Rosa Therapeutics (GLUE) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 44551000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 195.02% year-over-year to 44551000.0 in Q1 2026; TTM through Mar 2026 was 113416000.0, a 583.65% decrease from a year earlier, with the FY2025 full-year figure at 21980000.0, up 60.33% from the prior year.
- Income from Continuing Operations fell to 44551000.0 in Q1 2026 per GLUE's latest filing, from 29489000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 46885000.0 in Q1 2025 and bottomed at 64823000.0 in Q1 2022.
- The 5-year median for Income from Continuing Operations is 30310000.0 (2024), against an average of 23923235.29.
- Across the five-year window, Income from Continuing Operations sank 463.48% in 2022 and surged 246.58% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 30782000.0 in 2022, then decreased by 8.02% to 33252000.0 in 2023, then surged by 192.43% to 30734000.0 in 2024, then tumbled by 195.95% to 29489000.0 in 2025, then slumped by 51.08% to 44551000.0 in 2026.
- Per Business Quant, the three latest GLUE Income from Continuing Operations figures stand at 44551000.0 (Q1 2026), 29489000.0 (Q4 2025), and 27081000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Monte Rosa Therapeutics | 2.30 Bn | 1.62 Bn | - | -44.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.55 Mn |
| Dec 31, 2025 | -29.49 Mn |
| Sep 30, 2025 | -27.08 Mn |
| Jun 30, 2025 | -12.30 Mn |
| Mar 31, 2025 | 46.89 Mn |
| Dec 31, 2024 | 30.73 Mn |
| Sep 30, 2024 | -23.86 Mn |
| Jun 30, 2024 | -30.31 Mn |
| Mar 31, 2024 | -31.99 Mn |
| Dec 31, 2023 | -33.25 Mn |
| Sep 30, 2023 | -34.88 Mn |
| Jun 30, 2023 | -35.18 Mn |
| Mar 31, 2023 | -32.04 Mn |
| Dec 31, 2022 | -30.78 Mn |
| Sep 30, 2022 | -27.32 Mn |
| Jun 30, 2022 | -26.47 Mn |
| Mar 31, 2022 | -64.82 Mn |
| Dec 31, 2021 | -41.16 Mn |
| Sep 30, 2021 | -102.05 Mn |
| Jun 30, 2021 | -102.80 Mn |